Peter Attia MD229 ‒ Understanding cardiovascular disease risk, cholesterol, and apoB
At a glance
WHAT IT’S REALLY ABOUT
Why ApoB, Not 'Good' or 'Bad' Cholesterol, Drives Heart Disease
- Peter Attia argues atherosclerosis is the one inevitable disease of our species, that it starts decades before clinical events, and that first heart attacks are often fatal, so prevention must begin early.
- Attia explains that cholesterol is essential to life but travels in lipoproteins, that LDL and HDL are particles rather than 'bad' and 'good' cholesterol, and that the cholesterol inside them is identical.
- Allan Sniderman criticizes 10-year risk calculators as driven mostly by age and sex, arguing they delay prevention, and he advocates a causal, lifetime-oriented approach based on apoB or non-HDL cholesterol.
- Sniderman and Attia argue apoB counts all atherogenic particles and outperforms LDL-C, triglycerides, and HDL-C, citing Mendelian randomization evidence, discordance in metabolic disease, and the failure of HDL-raising drugs.
- Tom Dayspring and Attia argue that lowering plasma cholesterol does not deprive cells of cholesterol, and Attia concludes he now favors treating early and aggressively, aiming for apoB below roughly the 5th percentile (about 60 mg/dL).
IDEAS WORTH REMEMBERING
5 ideasAtherosclerosis starts far earlier than most people assume.
Attia describes autopsy sections showing atherosclerosis in people in their 20s and 30s, and says over half of men and a third of women who have a cardiac event have it before 65.
There is no good or bad cholesterol, only different lipoproteins.
Attia says the cholesterol in HDL and LDL is identical; LDL particles are the bad actors because they enter artery walls, and HDL-C is a snapshot that says nothing about HDL function.
Ten-year risk models hinder prevention of premature disease.
Sniderman says these calculations are driven mainly by age and sex, so risk looks low until 55 to 60 even though almost half of heart attacks and strokes happen before 60, and the disease is already advanced by then.
ApoB captures total atherogenic burden better than standard lipid numbers.
Because apoB counts all LDL, VLDL, IDL, and Lp(a) particles, it can reveal risk missed by LDL-C, such as in remnant type III dyslipoproteinemia or in metabolic syndrome discordance.
Mendelian randomization strengthens the causal case for apoB.
Sniderman says genes fixed at birth remove many confounders, and these studies show apoB is causal and includes the information in triglycerides and LDL-C, while HDL-C is not causal.
WORDS WORTH SAVING
5 quotesatherosclerosis is really the only inevitable disease of our species.
— Peter Attia
So the mantra that I like to say is no cholesterol, no life, period.
— Peter Attia
There is no phenotype without putting an apoB in there.
— Allan Sniderman
How can you pretend you've evaluated the system when you haven't counted the number of atherogenic particles?
— Allan Sniderman
there is no such thing as good cholesterol or bad cholesterol.
— Peter Attia
High quality AI-generated summary created from speaker-labeled transcript.
